Literature DB >> 6453676

Clodronate kinetics and dynamics.

K A Conrad, S M Lee.   

Abstract

Clodronate disodium (Cl2MDP) was given intravenously in doses of 3, 6 and 10 mg/kg to six men (aged 23 to 30 yr). Volume of distribution was 0.2720 +/- 0.0255 l/kg (mean +/- SD) after 3 mg/kg dose, 0.3037 +/- 0.0445 l/kg after 6 mg/kg, and 0.2528 +/- 0.417 l/kg after 10 mg/kg. The elimination rate constant was 0.3787 +/- 0.0546 hr(-1), 0.3492 +/- 0.0616 hr(-1), adn 0.3962 +/- 0.0358 hr(-1) after 3, 6, and 10 mg/kg. Corresponding total body clearances were 0.1026 /+- 0.0149, 0.1049 +/- 0.0159, and 0.0998 +/- 0.0172 l/kg/hr. Renal clearance accounted for 73% of total body clearance; 73% of the drug was extracted unchanged in the urine in 24 hr. After Cl2MDP serum phosphate decreased approximately 13%; this was associated at the 10 mg/kg dose with a transient fall in fractional phosphate excretion. There was no significant changes in the serum concentration of fractional excretion of calcium, sodium, or uric acid. Creatinine clearance and renal concentrating ability were not altered by Cl2MDP. After short-term administration Cl2MDP is excreted primarily by the kidney but has no significant effects on renal function.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6453676     DOI: 10.1038/clpt.1981.135

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  11 in total

1.  The clearance and bioavailability of pamidronate in patients with breast cancer and bone metastases.

Authors:  P T Daley-Yates; D J Dodwell; M Pongchaidecha; R E Coleman; A Howell
Journal:  Calcif Tissue Int       Date:  1991-12       Impact factor: 4.333

Review 2.  Bisphosphonates. Pharmacology and use in the treatment of tumour-induced hypercalcaemic and metastatic bone disease.

Authors:  H Fleisch
Journal:  Drugs       Date:  1991-12       Impact factor: 9.546

3.  Risedronate pharmacokinetics and intra- and inter-subject variability upon single-dose intravenous and oral administration.

Authors:  D Y Mitchell; W H Barr; R A Eusebio; K A Stevens; F P Duke; D A Russell; J D Nesbitt; J H Powell; G A Thompson
Journal:  Pharm Res       Date:  2001-02       Impact factor: 4.200

4.  Pamidronate distribution in pediatric renal and rheumatologic patients.

Authors:  Philip D Acott; Jaime A Wong; John F S Crocker; Bianca Lang; Patrick O'Regan; Kenneth W Renton
Journal:  Eur J Clin Pharmacol       Date:  2006-10-06       Impact factor: 2.953

Review 5.  Clodronate: a review of its use in breast cancer.

Authors:  M Hurst; S Noble
Journal:  Drugs Aging       Date:  1999-08       Impact factor: 3.923

6.  The tissue distribution of clodronate (dichloromethylene bisphosphonate) in mice. The effects of vehicle and the route of administration.

Authors:  J Mönkkönen; P Ylitalo
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1990 Jul-Sep       Impact factor: 2.441

Review 7.  Bisphosphonates and the treatment of bone disease in the elderly.

Authors:  A Johansen; M Stone; F Rawlinson
Journal:  Drugs Aging       Date:  1996-02       Impact factor: 3.923

Review 8.  Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy.

Authors:  R G G Russell; N B Watts; F H Ebetino; M J Rogers
Journal:  Osteoporos Int       Date:  2008-06       Impact factor: 4.507

9.  Influence of dichloromethylene diphosphonate on reactive oxygen species production by human neutrophils.

Authors:  R Serretti; P Core; S Muti; F Salaffi
Journal:  Rheumatol Int       Date:  1993       Impact factor: 2.631

Review 10.  Clodronic acid formulations available in Europe and their use in osteoporosis: a review.

Authors:  Bruno Frediani; Luca Cavalieri; Giovanni Cremonesi
Journal:  Clin Drug Investig       Date:  2009       Impact factor: 2.859

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.